TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25028536
Drug: Megace OS
Normalized name: megestrol acetate Oral Tablet [Megace]
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megace OS (800 mg/20 mL) in fasting state
Study: 25028536
Drug: Megace OS
Normalized name: megestrol acetate Oral Tablet [Megace]
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megace OS (800 mg/20 mL) in fed state
Study: 22930542
Drug: Intervention care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention care (multidisciplinary intervention including screening questionnaire, education, pain medication management, physiotherapy-guided exercise, communication with primary care physician)
Study: 7978433
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of lyophilized tetracaine with 0.2 mg epinephrine in 2.5 mL 10% dextrose, Group 0: immediately turned supine after spinal injection
Study: 7978433
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of lyophilized tetracaine with 0.2 mg epinephrine in 2.5 mL 10% dextrose, Group 6: 6 min in lateral decubitus then supine
Study: 7978433
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of lyophilized tetracaine with 0.2 mg epinephrine in 2.5 mL 10% dextrose, Group 12: 12 min in lateral decubitus then supine
Study: 7978433
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of lyophilized tetracaine with 0.2 mg epinephrine in 2.5 mL 10% dextrose, Group 18: 18 min in lateral decubitus then supine
Study: 2568061
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment every second week
Study: 23443764
Drug: Colloid preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid preload with gelofusine at 10 ml·kg(‐1)·h(‐1)
Study: 23443764
Drug: Colloid preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid preload with gelofusine at 5 ml·kg(‐1)·h(‐1)
Study: 23443764
Drug: Colloid preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid preload with gelofusine at 15 ml·kg(‐1)·h(‐1)
Study: 21398038
Drug: Pregabalin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75 mg twice daily to a maximum of 300 mg twice daily for 28 days)
Study: 20193529
Drug: micro pump
Normalized name: EpiQuin Micro Pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: micro pump administration of batroxobin
Study: 12742333
Drug: Uterine artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterine artery Doppler examination and 100 mg aspirin daily from Doppler examination through 36 weeks
Study: 9146853
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (20-160 ng kg-1 min-1)
Study: 9146853
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion with ganglionic blockade (trimetaphan)
Study: 3218950
Drug: Metoclopramide (MTC)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MTC) 10 mg IV
Study: 3218950
Drug: Metopimazine (MTP)
Normalized name: metopimazine
DrugBank: Metopimazine (DB13591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metopimazine (MTP) 10 mg IV
Study: 31778823
Drug: GB001 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB001 5 mg
Study: 26630400
Drug: PRP +
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP + IVR combined treatment
Study: 18782641
Drug: Exenatide twice
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide twice daily (10 µg)
Study: 9196108
Drug: Proportional assist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proportional assist ventilation (flow assist = 2 cm H2O/L/s plus volume assist = 4 cm H2O/L)
Study: 8485793
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg sublingually 20 min before induction of anaesthesia
Study: 24843712
Drug: Teneligliptin 20
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Teneligliptin 20 mg once daily
Study: 24014134
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ongoing antidiabetic therapy)
Study: 22218402
Drug: Immediate cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate cessation with nicotine patch therapy (2 weeks)
Study: 22218402
Drug: Reduction approach
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction approach with either 4 mg nicotine lozenge or ST brand switching
Study: 18235213
Drug: Metamizole 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizole 2 g/8 h i.v. (n = 8)
Study: 18235213
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg/4 h s.c. (n = 8)
Study: 15905654
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional physical therapy protocol)
Study: 10663966
Drug: Kainic acid
Normalized name: kainic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kainic acid (KA) administration
Study: 1464075
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg methyl prednisolone (three pulses)
Study: 2866062
Drug: Beta-adrenoceptor blocking
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoceptor blocking drugs (atenolol, propranolol, pindolol)
Study: 2866062
Drug: Propranolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (beta 1- and beta 2-blocker)
Study: 2866062
Drug: Beta-blockers (atenolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (atenolol, propranolol, pindolol)
Study: 25863804
Drug: DEB (Drug-Eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEB (Drug-Eluting Balloon)
Study: 18181808
Drug: Sequential anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential anticoagulation (citrate for the first 3.5 h, switching to 30‐min anticoagulation‐free hemodialysis)
Study: 15902989
Drug: Chokeberry juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chokeberry juice (150 mL daily, containing 23 mg/100 mL of anthocyanins)
Study: 8948373
Drug: Bovine immunoglobulin
Normalized name: Bovine immunoglobulin concentrate, cryptosporidium parvum
DrugBank: Cryptosporidium immune globulin (DB17785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine immunoglobulin concentrate (capsule form)
Study: 1661057
Drug: High titre
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titre varicella vaccine (5300 PFU)
Study: 1661057
Drug: Low titre
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low titre varicella vaccine (2000 PFU)
Study: 1661057
Drug: Combined varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined varicella and MMR vaccine (high titre)
Study: 1661057
Drug: Combined varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined varicella and MMR vaccine (low titre)
Study: 1661057
Drug: Single varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single varicella vaccine (both titre levels)
Study: 7213522
Drug: Quinidine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (oral and i.v. dosing)
Study: 7213522
Drug: Quinidine (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (i.v. dosing)
Study: 7213522
Drug: Quinidine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (oral dosing)
Study: 17021748
Drug: Stapled transanal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stapled transanal rectal resection (STARR)
Study: 19440010
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml lidocaine‐prilocaine cream perianally
Study: 19440010
Drug: Lidocaine‐prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine‐prilocaine cream perianally and intrarectally
Study: 17045952
Drug: Iron mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron mouthrinse (10mL of 10mM ferrous sulphate solution) after immersion in cola drink for 5min, followed by brushing after 1min or 30min.
Study: 17045952
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after immersion in cola drink.
Study: 11756369
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) pills
Study: 7855551
Drug: Clindamycin 6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 6.5 mg per kg body weight b.i.d. (children) or 300 mg t.i.d. (adults) for 10 days
Study: 7855551
Drug: Phenoxymethyl penicillin
Normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethyl penicillin 12.5 mg per kg body weight b.i.d. for 10 days
Study: 2526622
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (2 micrograms or 0.1 ml) intradermal hepatitis B vaccine
Study: 2526622
Drug: Standard (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard (20 micrograms or 1 ml) intramuscular hepatitis B vaccine
Study: 856569
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg reproterol
Study: 856569
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg orciprenaline
Study: 31558100
Drug: Dader Method
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dader Method for Pharmaceutical Care (PC)
Study: 28601627
Drug: 0.2 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg/kg dexmedetomidine
Study: 24073548
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination travoprost 0.004%/timolol 0.5%
Study: 24073548
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination dorzolamide 2%/timolol 0.5%
Study: 19180530
Drug: Brief self-administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief self-administered psychological intervention
Study: 9830258
Drug: typical antipsychotic
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: typical antipsychotic medication
Study: 7973751
Drug: Conservative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative and functional treatment with AIRCAST pneumatic leg braces, including a lower leg cast for 2 weeks followed by mobilization with protection from the brace.
Study: 2689314
Drug: Pulmo-Timelets (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmo-Timelets (600 mg theophylline)
Study: 2689314
Drug: Theophylline controlled-release
Normalized name: theophylline Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline controlled-release tablet (600 mg theophylline)
Study: 30366361
Drug: Genetically predicted
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically predicted circulating vitamin K₁ levels (per 1 nmol/L increase)
Study: 26822714
Drug: UC‐II (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC‐II (40 mg daily)
Study: 26822714
Drug: GC (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC (1500 mg G & 1200 mg C)
Study: 20542554
Drug: Allopurinol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (600 mg per day)
Study: 16085238
Drug: Aggressive combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive combined modality treatment arm for patients with poor prognosis
Study: 14989462
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with agalsidase alfa for 6 months
Study: 10579146
Drug: Sirolimus administered
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus administered after a high-fat meal (15 mg single dose)
Study: 10579146
Drug: Sirolimus administered
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus administered while fasting (15 mg single dose)
Study: 1899644
Drug: Continuous release
Normalized name: B Compound Continuous Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous release transdermal nitroglycerin (group 1)
Study: 1899644
Drug: Discontinuous release
Normalized name: morphine sulfate Extended Release Oral Tablet [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuous release transdermal nitroglycerin (group 2)
Study: 6179617
Drug: Adriamycin during
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin during induction of remission and maintenance therapy
Study: 31476539
Drug: Buccal‐based triangular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal‐based triangular flap (Group 1)
Study: 23506407
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of four dental implants with a fixed prosthesis (experimental arm)
Study: 22832126
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at 66 µg/kg/day
Study: 19650603
Drug: Oral-B Advantage
Normalized name: Advantage Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Advantage 123
Study: 12412826
Drug: Zomacton 4
Normalized name: Zomacton
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zomacton 4 mg/ml conventional syringe administration (Treatment A)
Study: 12412826
Drug: Zomacton 10
Normalized name: ZOMACTON 10mg Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zomacton 10 mg/ml conventional syringe administration (Treatment B)
Study: 12412826
Drug: Zomacton 10
Normalized name: ZOMACTON 10mg Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zomacton 10 mg/ml ZomaJet 2 Vision administration (Treatment C)
Study: 10212734
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of emotional, organic and neuropsychological measures (Hospital Anxiety and Depression Scale, Impact of Event Scale, Short Orientation Memory and Concentration Test, Rivermead Post‐Concussion Symptoms Questionnaire, Post‐Traumatic Amnesia) taken at 7‐10 days post-injury
Study: 30385451
Drug: Finger prick
Normalized name: prickly pear fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finger prick autologous blood (FAB) treatment
Study: 26542271
Drug: PT (Physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT (Physical Therapy) 3 times/week for 4 weeks
Study: 25138681
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive patch applied to buttocks
Study: 25138681
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive patch applied to outer upper arm
Study: 25138681
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive patch applied to lower abdomen
Study: 25138681
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive patch applied to any site
Study: 19908948
Drug: Carisoprodol 250
Normalized name: carisoprodol 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carisoprodol 250 mg
Study: 15378438
Drug: Tafenoquine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 400 mg (base) daily for 3 days, followed by single monthly 400-mg doses (n = 104)
Study: 11162345
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment condition
Study: 2485152
Drug: Cyclooxygenase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclooxygenase inhibitors (azapropazone) and aprotinin
Study: 2485152
Drug: Non-steroidal antiphlogistic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal antiphlogistic drugs
Study: 1148993
Drug: Low-dose preoperative
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose preoperative irradiation (2000-2500 rads/10 fractions/12 days)
Study: 1148993
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose preoperative irradiation (3150 rads)
Study: 22476244
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (1,500 mg/day) plus exercise therapy
Study: 19502478
Drug: Individual‐Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual‐Based Treatment (IBT)
Study: 16861432
Drug: Positive intravascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive intravascular fluid balance of 0-1000 mL (Group 1)
Study: 16861432
Drug: Positive intravascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive intravascular fluid balance of 1000-2000 mL (Group 2)
Study: 12942587
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB) 500 mg
Study: 8767376
Drug: Mechanical lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical lavage with 2 l of polyethylene glycol (PEG) solution combined with a laxative (group A, n = 50)
Study: 8767376
Drug: Lavage with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavage with 4 l of PEG alone (group B, n = 50)
Study: 6752563
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg dimethpyrindene (Fenistil) and 5 mg/kg cimetidine (Tagamet)
Study: 6752563
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg dimethpyrindene and 10 mg/kg cimetidine
Study: 6752563
Drug: H1- +
Normalized name: Histamine H1 Receptor Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1- + H2-receptor antagonists
Study: 31800611
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine (30 mg) before surgery
Study: 28286194
Drug: Rectal tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal tacrolimus (0.5 mg/mL)
Study: 23031464
Drug: E2 (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 (125 mg PFA/kg BD)
Study: 23031464
Drug: E3 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: E3 (250 mg PFA/kg BD)
Study: 11448249
Drug: Clonidine (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (4, 6, and 8 mcg/kg/day)
Study: 30479242
Drug: Collaborative shared
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collaborative shared care (CSC) program between traditional and faith healers (T&FHs) and biomedical providers for the treatment of psychotic disorders
Study: 28189771
Drug: Tiotropium 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 5 μg (2 puffs of 2.5 μg)
Study: 28189771
Drug: Tiotropium 2.5
Normalized name: TIOTROPIUM 2.5MCG/ACTUAT 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 2.5 μg (2 puffs of 1.25 μg)
Study: 25915834
Drug: Topical EBI-005
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical EBI-005 (5 mg/mL)
Study: 23635736
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored therapy (n=62)
Study: 18385391
Drug: Niacinamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacinamide (500 to 1500 mg/d)
Study: 18385391
Drug: Niacinamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacinamide (500 to 1500 mg/d) among compliant patients
Study: 12915954
Drug: Menthol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthol (100 mg)
Study: 9137841
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake blockers
Study: 8212819
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of B-WC vaccine at 7, 14, or 28-42 day intervals
Study: 8212819
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of B-WC vaccine at 3-day intervals
Study: 8212819
Drug: Different time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different time intervals tested (3-42 days) for vibriocidal antibody responses
Study: 8212819
Drug: B-WC vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-WC vaccine with sodium bicarbonate powder
Study: 3940333
Drug: Gentle breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentle breast stimulation for 1.5 hours in hospital and then for three hours daily for three days at home.
Study: 31996978
Drug: FV+ (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: FV+ (standard food parcel plus the recommended daily amount of fruit and vegetables)
Study: 31996978
Drug: Snacks-+FV+ (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snacks-+FV+ (standard food parcel with replacement of unhealthy snacks by staple foods plus the recommended daily amount of fruit and vegetables)
Study: 27833172
Drug: Cranberry supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry supplementation (1500 mg cranberry fruit powder for a mean of 30 days)
Study: 10485720
Drug: Nevirapine 200
Normalized name: nevirapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 200 mg orally at onset of labour and 2 mg/kg to babies within 72 h of birth